风险分层下老年人RSV疫苗接种的成本效果
研究模拟≥75岁及50-74岁有慢性病老年人接种RSV疫苗的成本效果与风险获益。结果:接种避免的QALY损失超过疫苗相关GBS;成本效果随年龄、风险条件和保护时长变化,60-74岁无慢性病者ICER高。
要点
- ≥75岁接种蛋白亚单位疫苗(3年保护)每QALY成本45,769美元。
- 60-74岁至少一种慢性病者接种蛋白亚单位疫苗(3年保护)每QALY成本21,721美元。
- 60-74岁无慢性病者接种ICER为287,793至503,328美元/QALY,成本效果差。
核心结论
- RSV疫苗接种避免的RSV相关QALY损失多于疫苗相关GBS。
- 社会成本效果随年龄、风险条件和疫苗保护时长显著变化。
- 60-74岁无慢性病者接种的增量成本效果比高。
研究设计与样本
- 模拟RSV疫苗接种的成本效果与风险获益权衡。
- 目标人群为≥75岁成人及50-74岁有慢性病成人。
- 数据来自疫苗试验、同行评议文献、观察性VE研究和RSV-NET等监测网络。
- 假设疫苗保护持续2至3年。
主要发现
- ≥75岁接种蛋白亚单位疫苗(3年保护)成本为45,769美元/QALY(95%UI:25,505-84,871)。
- ≥75岁接种mRNA疫苗(2年保护)成本为100,571美元/QALY(UI:58,277-225,885)。
- ≥75岁接种mRNA疫苗(3年保护)成本为70,731美元/QALY(UI:42,069-159,451)。
- 60-74岁至少一种慢性病者接种蛋白亚单位疫苗(3年保护)成本为21,721美元/QALY(UI:cost-saving-120,989)。
- 60-74岁至少一种慢性病者接种mRNA疫苗(2年保护)成本为85,781美元/QALY(UI:3,368-409,467)。
关键数值与推荐
- ≥75岁:蛋白亚单位疫苗3年保护45,769美元/QALY;mRNA疫苗2年保护100,571美元/QALY;mRNA疫苗3年保护70,731美元/QALY。
- 60-74岁至少一种慢性病:蛋白亚单位疫苗3年保护21,721美元/QALY;mRNA疫苗2年保护85,781美元/QALY;mRNA疫苗3年保护50,864美元/QALY。
- 50-59岁至少一种慢性病:蛋白亚单位疫苗3年保护43,070美元/QALY;mRNA疫苗2年保护152,293美元/QALY;mRNA疫苗3年保护95,182美元/QALY。
- 60-74岁无慢性病:ICER为287,793至503,328美元/QALY。
- 若RSV疾病发病率、费用或死亡率更高,接种更具成本效果。
临床怎么用
- 可为≥75岁及50-74岁有慢性病者评估RSV疫苗接种的成本效果。
- 选择疫苗时需考虑保护时长对成本效果的影响。
- 60-74岁无慢性病者接种成本效果差,决策需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory syncytial virus (RSV) disproportionately affects older adults with chronic conditions. RSV vaccines are effective but costly, and post-licensure studies suggest increased risk of Guillain-Barre syndrome (GBS). We evaluated cost-effectiveness and risk-benefit trade-offs of RSV vaccination by simulating RSV vaccination in adults aged ≥75 years and in adults aged 50-74 years with chronic conditions associated with increased risk of severe RSV disease. Data came from vaccine trials, peer-reviewed literature, observational vaccine effectiveness (VE) studies, and surveillance networks such as RSV-NET. Vaccine protection was assumed to last between 2 and 3 years. We estimated RSV vaccination averts more quality-adjusted life-years (QALYs) from RSV than vaccine-associated GBS. Societal cost-effectiveness varies substantially depending on age, risk condition, and duration of VE. RSV vaccination of adults aged ≥75 years costs $45,769 (95% uncertainty interval, UI: $25,505-$84,871) per quality-adjusted life-year (QALY) for protein subunit vaccines with 3 years of effectiveness; $100,571 (UI: $58,277-$225,885)/QALY for mRNA vaccine with 2 years of effectiveness; and $70,731 (UI: $42,069-$159,451) for mRNA vaccine with 3 years of effectiveness. Vaccination of adults aged 60-74 years with at least one chronic condition costs $21,721 (UI: cost-saving-$120,989)/QALY for protein subunit vaccines with 3 years effectiveness; $85,781 (UI: $3368-$409,467)/QALY for mRNA vaccine with 2 years of effectiveness; and $50,864 (UI: $3668-$249,938)/QALY for mRNA vaccine with 3 years of effectiveness. Vaccination of adults aged 50-59 years with at least one chronic condition costs $43,070 (UI: cost-saving-$266,769)/QALY for protein subunit vaccines with 3 years of effectiveness; $152,293 (UI: $1154-$811,138)/QALY for mRNA vaccine with 2 years of effectiveness; and $95,182 (UI: cost-saving-$682,508) for mRNA vaccine with 3 years of effectiveness. Regardless of the vaccine used, vaccination of adults aged 60-74 years without chronic conditions has high incremental cost effectiveness ratios ($287,793 to $503,328/QALY). If RSV disease had higher incidence, costs, or mortality, vaccination would be more cost-effective.
引用
- Hutton DW, Prosser LA, Ortega-Sanchez IR, et al. Evaluating the cost-effectiveness of respiratory syncytial virus vaccination among risk-stratified older adults. Vaccine. 2026. PMID: 42571751. doi:10.1016/j.vaccine.2026.129023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。